This is the best time to take an exam to boost your chances of passing, study finds
*
SIGN UP
I would like to be emailed about offers, events and updates from The Independent. Read our Privacy notice
Midday may be the best time to take an oral exam, interview for a job, or even go on trial, a new study has found.
Researchers at Italy's University of Messina found a significant difference in students' pass rates in the late morning compared to early morning or late afternoon.
At 12pm the students' passing rate was 72 per cent, compared to 54 per cent at 8am and 51 per cent at 4pm. Pass rates at 11am and 1pm were slightly lower at 67 per cent.
'We show that academic assessment outcomes vary systematically across the day, with a clear peak in passing rates around midday,' said Professor Carmelo Mario Vicario.
'Students were more likely to pass in late morning compared with early morning or late afternoon,' he said. 'We believe this pattern could extend to job interviews or any evaluative process scheduled throughout the day.'
The study was based on the outcome of 104,552 assessments delivered by 680 examiners for 1,243 courses. The researchers chose to look at university oral exams, which are more subjective and aren't marked solely on correct answers, but also on delivery.
It follows research showing that judges are more likely to rule in favour of a defendant at the start of sessions or after meal breaks.
However, it is thought that this could also come down to the types of cases that are heard at different times of day.
The study's author believes the findings could extend to job interviews
( Getty/iStock )
While the study could not identify the exact cause, it said the midday peak was consistent with evidence that cognitive performance improves over the morning and declines during the afternoon.
The report said this could be due to the students' falling energy levels, as well as professors', who may give a harsher mark if they are experiencing decision fatigue.
Researchers also said that it could be a result of students and professors competing chronotypes, the body's natural preference of sleeping times.
'People in their early 20s are usually night owls, while people in their 40s or older tend to be morning larks. The students might be least cognitively sharp at the time when the professors are most alert.'
Prof Vicario suggested that to counteract these effects, students would benefit from better sleep, mental breaks, and scheduling exams outside of personal low periods.
'For institutions, delaying morning sessions or clustering key assessments in the late morning may improve outcomes.
'We believe this pattern could extend to job interviews or any evaluative process scheduled throughout the day.
'We would be very interested in investigating whether hiring decisions, too, fluctuate in fairness or outcome depending on time of day.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
31 minutes ago
- Reuters
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday. The new late-stage study will target people who are at risk of cognitive decline and aim to slow down the emergence of symptoms or prevent them fully, the report said, citing a statement. The new pre-clinical study is the third largest late-stage trial that the company has announced for its drug trontinemab, which uses an experimental technology called brain shuttle to ferry medicine past the protective blood-brain barrier, according to the report. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently with Lilly's Alzheimer's drug Kisunla getting recommendation from the European Medicines Agency (EMA) last week. Reuters could not immediately verify the report. Roche did not immediately respond to a request for a comment. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi, and Eli Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They also carry hefty price tags and the risk of serious brain swelling and bleeding.
The Independent
5 hours ago
- The Independent
This fuzzy animal friend may be the key to treating schizophrenia
Llamas – likely without red pajamas – may hold the key to treating schizophrenia. The serious brain disorder causes people to interpret reality abnormally, and affects approximately 3.7 million U.S. adults between the ages of 18 to 65 years old, according to the nonprofit RTI International. But the domesticated South American woolly animal might be be able to help. French researchers said this week that they had used llama antibodies, or proteins that help to protect the immune system, to design a tiny fragment of an antibody known as a 'nanobody' that will trigger a neurotransmitter in the brain involved in regulating neural activity. Neurotransmitters are chemical molecules that carry messages or signals from one nerve cell to the next target cell, according to the Cleveland Clinic. No llamas were harmed in the study and researchers can identify nanobodies in a petri dish. In the past, llama antibodies have also proven effective in fighting Covid and other 'SARS-like' viruses. When scientists at the Institute of Functional Genomics injected the molecule into the veins or the muscles, it was able to break the blood-brain barrier and effectively reach brain receptors. The barrier is a a tightly locked layer of cells that defend your brain from harmful substances. Studying the impact of the nanobodies in two tests using mice, the researchers found that they corrected cognitive deficits that were observed. There was an improvement of cognitive function with just one shot, and a prolonged effect over one week. Clinical studies are now required to show that their findings could be a new avenue of treatment for schizophrenia. "In humans obviously we don't know [yet], but in mice yes, it is sufficient to treat most deficits of schizophrenia," molecular biologist Jean-Philippe Pin told Newsweek.. He was a co-author of the research which was published in the journal Nature. Pin said that medications currently given to schizophrenia patients "treat the symptoms well, but less the cognitive deficits." The cause of the chronic condition remains unknown, but the World Health Organization says it is thought that an interaction between genes and a range of environmental factors may be the reason. The exact prevalence of schizophrenia is difficult to measure. Some have tied cases in Canada to cannabis use. Although schizophrenia can occur at any age, people are typically diagnosed between the ages of 16 and 30. Symptoms vary from person to person. There is no cure, but it can be treated through antipsychotic medications, talk therapy, and self-management strategies, the National Alliance on Mental Illness says. The study's authors hope to add this strategy to the list. 'This research confirms the potential of nanobodies as a new therapeutic strategy for acting on the brain, with their use eventually being broadened to include the treatment of other neurological illnesses,' the institute said in a statement.
The Guardian
6 hours ago
- The Guardian
Thousands of tons of invasive seaweed ‘overwhelming' Spanish beaches
Thousands of tonnes of an aggressive invasive seaweed from south-east Asia are piling up on the beaches of the strait of Gibraltar and Spain's southern coast in what local environmentalists say is a major threat to the region's biodiversity. Since May, the local authority in Cádiz has removed 1,200 tonnes of the alga Rugulopteryx okamurae from La Caleta, the city's most popular beach, including 78 tonnes in a single day. 'We're completely overwhelmed. This is an environmental catastrophe,' said José Carlos Teruel, responsible for Cádiz city council's beaches. 'Whenever the wind is westerly, we know we're in for another wave of seaweed.' As with many other invasive marine species, the alga is thought to arrive in the ballast tanks of ships which pass through the Suez canal and then discharge their tanks in the Mediterranean. In little more than a decade the species has colonised the strait of Gibraltar, much of Spain's southern coast, the Canary Islands, the Azores, and, farther north, the Cantabrian sea and the Basque Country. 'It was first spotted 10 years ago in Ceuta, Spain's north African enclave, by a researcher from Málaga university, but the authorities are always too slow to react,' said Juan José Vergara, a professor of biology at the University of Cádiz. 'In the first phase of an invasion such as this it can be controlled. It's like catching cancer early on before it spreads,' Vergara said, adding that what washes ashore is a fraction of what is underwater. 'But now the scale of it makes it impossible to control. In other seaweed invasions we've seen things revert to normal after a period of 10-15 years but many scientists say they've never seen an invasion on this scale.' The seaweed is having a major impact on the local economy, firstly on tourism in Cádiz and nearby Tarifa, a town popular with windsurfers, and on fishing because it traps fishers' nets and lines and also sucks oxygen out of the water. Then there's the cost to the taxpayer of disposing of it. Perhaps most worrying is its impact on biodiversity. On the beach at La Caleta, the seaweed has driven out many indigenous plants. It is unclear whether the damage is temporary or irreversible. The alga attaches itself to rocks and other surfaces and is also free-floating, wiping out native species of seaweed. It has no predators in the region and its capacity to reproduce both sexually and asexually and to absorb toxins makes it virtually impossible to eradicate, experts say. At present the seaweed is dumped in landfill sites. Vergara said a local business that recycles seaweed into drinks containers or to use as fuel and fertiliser has sought permission to use Rulopteryx okamuraeas as a biomass to produce energy. However, Spain's law on invasive species prohibits their commercial exploitation unless they pose a threat to health and safety or to further their eradication, a caveat that would seem to apply to Rulopteryx okamuraeas. This week the government in Andalucía launched a four-part plan to confront the crisis based on research, monitoring and education, and which includes options for recycling the seaweed. To use it as biomass the regional government will have to negotiate with Spain's environment ministry but Vergara said that even if an agreement is reached, it can only be part of the solution. 'It's an interesting idea but I doubt it will be able to eradicate or even significantly diminish the intensity of the invasion when hundreds of thousands of tonnes can wash up on a single beach,' he said.
